Joseph Tuscano
University of California, Davis · UC Davis Comprehensive Cancer Center · City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph Tuscano as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:01 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02542657 · Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple MyelomaJoseph Tuscano · completed · Myeloma · principal investigator
- Ph2NCT01811368 · Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaJoseph Tuscano · unknown · Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma · principal investigator
- Ph2NCT01736943 · Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaJoseph Tuscano · completed · Acute Myelogenous Leukemia · principal investigator
- Ph1NCT01729806 · Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaNational Cancer Institute (NCI) · completed · CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT01716208 · Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic LymphomaJoseph Tuscano · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01316523 · Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's LymphomaUniversity of California, Davis · terminated · Non Hodgkin's Lymphoma · principal investigator
- Ph1NCT00538187 · Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaNational Cancer Institute (NCI) · terminated · Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studiesI01BX004669 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2020 to 2025Same name and institution; not confirmed by an ID
- CD22-targeted Therapeutics for the Treatment of Lung CancerI01BX000961 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2013 to 2016Same name and institution; not confirmed by an ID
- PHASE II TRIAL OF BEVACIZUMAB VS BEVACIZUMAB, THALIDOMIDE FOR RELAPSED/REFRACTORM01RR019975 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2004 · $6,474 awarded in 2004Same name and institution; not confirmed by an ID
- GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORMK08CA077331 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 1998 to 2000 · $84,780 awarded in 2000Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2008 to 2026Named on NCT01729806
- Phase I Molecular and Clincal Pharmacodynamic TrialsU01CA062505 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EDWARD M NEWMAN · fiscal years 2009 to 2013Named on NCT01729806, NCT00538187
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT01729806
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT01729806
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:01 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.J Clin Oncol · 2008334 citationsRCR 6.9
- 238 citationsRCR 6.3
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.Br J Haematol · 2009216 citationsRCR 4.5
- 107 citationsRCR 2.4
- Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.Br J Haematol · 201471 citationsRCR 1.9
- Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.Am J Hematol · 200263 citationsRCR 2.0
- 62 citationsRCR 1.8
- 60 citationsRCR 1.4
- 56 citationsRCR 1.5